Skip to main content
. Author manuscript; available in PMC: 2022 May 4.
Published in final edited form as: J Adolesc Health. 2018 Feb 8;62(4):417–423. doi: 10.1016/j.jadohealth.2017.10.017

Table 2.

Logistic regression models of STI/HIV services by contraceptive type among sexually active adolescent and young adult women 15–24 years, 2011–2015 National Survey of Family Growth

Chlamydia testing Any STI testing HIV testing Sexual risk assessment (2013–2015 only)
PR (95% CI)
(n = 2,005)
aPR (95% CI)
(n = 1,976)
PR (95% CI)
(n = 2,007)
aPR (95% CI)
(n = 1,978)
PR (95% CI)
(n = 2,017)
aPR (95% CI)
(n = 1,988)
PR (95% CI)
(n = 971)
aPR (95% CI)
(n = 950)
LARC versus moderately effective
 Continuing LARC .91 (.68–1.21) .88 (.65–1.20) .91 (.70–1.17) .84 (.64–1.12) .60 (.39–.93) .52 (.32–.85) .76 (.60–.97) .78 (.61–1.01)
 New LARC 1.10 (.82–1.47) .98 (.73–1.30) 1.06 (.81–1.39) .89 (.67–1.20) 1.12 (.69–1.82) .88 (.50–1.54) .99 (.79–1.24) 1.01 (.80–1.26)
LARC versus less effective
 Continuing LARC 1.16 (.85–1.57) 1.17 (.87–1.59) 1.12 (.85–1.48) 1.11 (.83–1.48) .86 (.54–1.36) .84 (.50–1.40) 1.03 (.76–1.40) 1.05 (.78–1.41)
 New LARC 1.40 (1.04–1.90) 1.30 (.95–1.79) 1.32 (.99–1.75) 1.18 (.86–1.61) 1.60 (.96–2.64) 1.41 (.81–2.46) 1.34 (1.01–1.78) 1.35 (1.03–1.76)
LARC versus no contraception
 Continuing LARC 1.52 (1.09–2.12) 1.52 (1.08–2.15) 1.32 (.99–1.74) 1.29 (.95–1.75) .78 (.48–1.25) .77 (.45–1.31) 1.02 (.74–1.41) 1.11 (.80–1.55)
 New LARC 1.84 (1.34–2.53) 1.69 (1.24–2.29) 1.54 (1.16–2.06) 1.37 (1.00–1.87) 1.45 (.86–2.43) 1.30 (.73–2.32) 1.32 (1.02–1.72) 1.43 (1.11–1.85)

Adjusted models include age, race/ethnicity, insurance status, mother’s highest level of education, usual source of care, live birth in the past year, number of partners, and data collection period. Bold findings indicate confidence interval does not overlap with 1.

aPR = adjusted prevalence ratio; CI = confidence interval; LARC = long-acting reversible contraception; PR = prevalence ratio.